Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darren Pan

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Expert Opinion on Investigational Drugs|May 27, 2025
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive reviewDarren Pan, Anupama Kumar, Jodi J Lipof, et al.
Bone Marrow Transplantation|July 31, 2024
Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myelomaZachary M Avigan, Suzanne Arinsburg, Darren Pan, et al.
Bone Marrow Transplantation|October 18, 2024
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myelomaZachary M Avigan, Suzanne Arinsburg, Darren Pan, et al.
Heart & Lung : the Journal of Critical Care|June 5, 2021
Pre-hospital antiplatelet medication use on COVID-19 disease severityDarren Pan, Ada Ip, Serena Zhan, et al.
Blood Advances|October 9, 2024
Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survivalZachary M Avigan, Saoirse Bodnar, Darren Pan, et al.
Bone Marrow Transplantation|May 3, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myelomaDarren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
Cancer Medicine|December 18, 2021
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myelomaDarren Pan, Jonathan L Kaufman, Myo Htut, et al.
Bone Marrow Transplantation|March 30, 2026
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myelomaDarren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
American Journal of Hematology|April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps ConferenceAjai Chari, Caitlin Costello, Amrita Krishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapyZachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Expert Opinion on Investigational Drugs|May 27, 2025
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive reviewDarren Pan, Anupama Kumar, Jodi J Lipof, et al.
Bone Marrow Transplantation|July 31, 2024
Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myelomaZachary M Avigan, Suzanne Arinsburg, Darren Pan, et al.
Bone Marrow Transplantation|October 18, 2024
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myelomaZachary M Avigan, Suzanne Arinsburg, Darren Pan, et al.
Heart & Lung : the Journal of Critical Care|June 5, 2021
Pre-hospital antiplatelet medication use on COVID-19 disease severityDarren Pan, Ada Ip, Serena Zhan, et al.
Blood Advances|October 9, 2024
Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survivalZachary M Avigan, Saoirse Bodnar, Darren Pan, et al.
Bone Marrow Transplantation|May 3, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myelomaDarren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
Cancer Medicine|December 18, 2021
Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myelomaDarren Pan, Jonathan L Kaufman, Myo Htut, et al.
Bone Marrow Transplantation|March 30, 2026
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myelomaDarren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
American Journal of Hematology|April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps ConferenceAjai Chari, Caitlin Costello, Amrita Krishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapyZachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
Pageof 3